Literature DB >> 34038650

Pediatric Lipid Disorders.

Scott Leopold, Justin P Zachariah.   

Abstract

Current scientific evidence has proven that atherosclerosis is a process that begins in childhood and tracks into adulthood, likely culminating in adverse cardiovascular events such as coronary artery disease, peripheral artery disease, and stroke. In addition, the obesity epidemic and increasing awareness of genetic lipid disorders has made the understanding and management of lipid disorders necessary for pediatricians. Childhood offers a unique opportunity for preventing, modifying, or eliminating risk factors and, in doing so, reversing or slowing the process of atherosclerosis. In general, management involves targeted lifestyle interventions such as strict dietary changes and increases in physical activity. In some circumstances, pharmacotherapy, even in childhood, is warranted. [Pediatr Ann. 2021;50(3):e105-e112.].

Entities:  

Mesh:

Year:  2021        PMID: 34038650      PMCID: PMC8544611          DOI: 10.3928/19382359-20210218-01

Source DB:  PubMed          Journal:  Pediatr Ann        ISSN: 0090-4481            Impact factor:   1.132


  47 in total

1.  Tracking of serum lipid levels, blood pressure, and body mass index from childhood to adulthood: the Cardiovascular Risk in Young Finns Study.

Authors:  Jonna Juhola; Costan G Magnussen; Jorma S A Viikari; Mika Kähönen; Nina Hutri-Kähönen; Antti Jula; Terho Lehtimäki; Hans K Åkerblom; Matti Pietikäinen; Tomi Laitinen; Eero Jokinen; Leena Taittonen; Olli T Raitakari; Markus Juonala
Journal:  J Pediatr       Date:  2011-04-22       Impact factor: 4.406

2.  The Muscatine hyperlipidemia family study program.

Authors:  H G Schrott; K A Bucher; W R Clarke; R M Lauer
Journal:  Prog Clin Biol Res       Date:  1979

3.  Mutational analysis and genotype-phenotype relation in familial hypercholesterolemia: The SAFEHEART registry.

Authors:  Mafalda Bourbon; Ana Catarina Alves; Rodrigo Alonso; Nelva Mata; Pedro Aguiar; Teresa Padró; Pedro Mata
Journal:  Atherosclerosis       Date:  2017-04-06       Impact factor: 5.162

4.  Correlates of Achieving Statin Therapy Goals in Children and Adolescents with Dyslipidemia.

Authors:  Michael M Mendelson; Todd Regh; James Chan; Annette Baker; Heather Harker Ryan; Nicole Palumbo; Philip K Johnson; Suzanne Griggs; Meera Boghani; Nirav K Desai; Elizabeth Yellen; Lucy Buckley; Matthew W Gillman; Justin P Zachariah; Dionne Graham; Sarah D de Ferranti
Journal:  J Pediatr       Date:  2016-08-31       Impact factor: 4.406

5.  Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.

Authors:  William E Boden; Jeffrey L Probstfield; Todd Anderson; Bernard R Chaitman; Patrice Desvignes-Nickens; Kent Koprowicz; Ruth McBride; Koon Teo; William Weintraub
Journal:  N Engl J Med       Date:  2011-11-15       Impact factor: 91.245

6.  Cardiovascular Risk Reduction in High-Risk Pediatric Patients: A Scientific Statement From the American Heart Association.

Authors:  Sarah D de Ferranti; Julia Steinberger; Rebecca Ameduri; Annette Baker; Holly Gooding; Aaron S Kelly; Michele Mietus-Snyder; Mark M Mitsnefes; Amy L Peterson; Julie St-Pierre; Elaine M Urbina; Justin P Zachariah; Ali N Zaidi
Journal:  Circulation       Date:  2019-03-26       Impact factor: 29.690

7.  Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC).

Authors:  Antonio J Vallejo-Vaz; Martina De Marco; Christophe A T Stevens; Asif Akram; Tomas Freiberger; G Kees Hovingh; John J P Kastelein; Pedro Mata; Frederick J Raal; Raul D Santos; Handrean Soran; Gerald F Watts; Marianne Abifadel; Carlos A Aguilar-Salinas; Mutaz Al-Khnifsawi; Fahad A AlKindi; Fahad Alnouri; Rodrigo Alonso; Khalid Al-Rasadi; Ahmad Al-Sarraf; Tester F Ashavaid; Christoph J Binder; Martin P Bogsrud; Mafalda Bourbon; Eric Bruckert; Krzysztof Chlebus; Pablo Corral; Olivier Descamps; Ronen Durst; Marat Ezhov; Zlatko Fras; Jacques Genest; Urh Groselj; Mariko Harada-Shiba; Meral Kayikcioglu; Katarina Lalic; Carolyn S P Lam; Gustavs Latkovskis; Ulrich Laufs; Evangelos Liberopoulos; Jie Lin; Vincent Maher; Nelson Majano; A David Marais; Winfried März; Erkin Mirrakhimov; André R Miserez; Olena Mitchenko; Hapizah M Nawawi; Børge G Nordestgaard; György Paragh; Zaneta Petrulioniene; Belma Pojskic; Arman Postadzhiyan; Ashraf Reda; Željko Reiner; Wilson E Sadoh; Amirhossein Sahebkar; Abdullah Shehab; Aleksander B Shek; Mario Stoll; Ta-Chen Su; Tavintharan Subramaniam; Andrey V Susekov; Phivos Symeonides; Myra Tilney; Brian Tomlinson; Thanh-Huong Truong; Alexandros D Tselepis; Anne Tybjærg-Hansen; Alejandra Vázquez-Cárdenas; Margus Viigimaa; Branislav Vohnout; Elisabeth Widén; Shizuya Yamashita; Maciej Banach; Dan Gaita; Lixin Jiang; Lennart Nilsson; Lourdes E Santos; Heribert Schunkert; Lale Tokgözoğlu; Josip Car; Alberico L Catapano; Kausik K Ray
Journal:  Atherosclerosis       Date:  2018-10       Impact factor: 5.162

8.  Normal growth in high-risk hyperlipidemic children and adolescents with dietary intervention.

Authors:  M S Jacobson; S Tomopoulos; C L Williams; M R Arden; R J Deckelbaum; T J Starc
Journal:  Prev Med       Date:  1998 Nov-Dec       Impact factor: 4.018

9.  Noninvasive assessment of subclinical atherosclerosis in children and adolescents: recommendations for standard assessment for clinical research: a scientific statement from the American Heart Association.

Authors:  Elaine M Urbina; Richard V Williams; Bruce S Alpert; Ronnie T Collins; Stephen R Daniels; Laura Hayman; Marc Jacobson; Larry Mahoney; Michele Mietus-Snyder; Albert Rocchini; Julia Steinberger; Brian McCrindle
Journal:  Hypertension       Date:  2009-09-03       Impact factor: 10.190

Review 10.  Screening and treatment for lipid disorders in children and adolescents: systematic evidence review for the US Preventive Services Task Force.

Authors:  Elizabeth M Haney; Laurie Hoyt Huffman; Christina Bougatsos; Michele Freeman; Robert D Steiner; Heidi D Nelson
Journal:  Pediatrics       Date:  2007-07       Impact factor: 7.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.